Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery

Future Medicinal Chemistry

Volumn 6, Issue 6, 2014, Pages 617-639

  Zimmermann, Markus O ^a   Lange, Andreas ^a   Wilcken, Rainer ^a,b,c   Cieslik, Markus B ^a   Exner, Thomas E ^a   Joerger, Andreas C ^b   Koch, Pierre ^a   Boeckler, Frank M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HALOGEN; PROTEIN P53; MOLECULAR LIBRARY; PROTEIN; PROTEIN BINDING;

BINDING SITE; CHEMICAL BINDING; CHEMICAL BOND; CRYSTALLOGRAPHY; DRUG DEVELOPMENT; EVOLUTION; GEOMETRY; MOLECULAR INTERACTION; MOLECULAR LIBRARY; MOLECULAR PROBE; NUCLEOPHILICITY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; STRENGTH; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; PHARMACOLOGY; PROTEIN DATABASE;

ANIMALS; BINDING SITES; DATABASES, PROTEIN; DRUG DESIGN; HALOGENS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84902117987     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.20     Document Type: Review

References (169)

1. Guthrie F. XXVIII. On the iodide of iodammonium. J. Chem. Soc. 16, 239-244 (1863).
2. Hassel O, Hvoslef J. The structure of bromine 1,4-dioxanate. Acta Chem. Scand. 8, 873-873 (1954).
3. Benesi HA, Hildebrand JH. A spectrophotometric investigation of the interaction of iodine with aromatic hydrocarbons. J. Am. Chem. Soc. 71(8), 2703-2707 (1949).
4. Clark T, Hennemann M, Murray JS, Politzer P. Halogen bonding: The sigma-hole. J. Mol. Model. 13(2), 291-296 (2007).
5. Lommerse JPM, Stone AJ, Taylor R, Allen FH. The nature and geometry of intermolecular interactions between halogens and oxygen or nitrogen. J. Am. Chem. Soc. 118(13), 3108-3116 (1996).
6. Ramasubbu N, Parthasarathy R, Murray-Rust P. Angular preferences of intermolecular forces around halogen centers: Preferred directions of approach of electrophiles and nucleophiles around carbon-halogen bond. J. Am. Chem. Soc. 108(15), 4308-4314 (1986).
7. Politzer P, Lane P, Concha MC, Ma YG, Murray JS. An overview of halogen bonding. J. Mol. Model. 13(2), 305-311 (2007).
8. Riley KE, Hobza P. Investigations into the nature of halogen bonding including symmetry adapted perturbation theory analyses. J. Chem. Theory Comput. 4(2), 232-242 (2008).
9. Politzer P, Murray JS, Clark T. Halogen bonding: An electrostatically- driven highly directional noncovalent interaction. Phys. Chem. Chem. Phys. 12(28), 7748-7757 (2010).
10. Politzer P, Murray JS, Clark T. Halogen bonding and other sigma-hole interactions: A perspective. Phys. Chem. Chem. Phys. 15(27), 11178-11189 (2013).
11. Metrangolo P, Neukirch H, Pilati T, Resnati G. Halogen bonding based recognition processes: A world parallel to hydrogen bonding. Acc. Chem. Res. 38(5), 386-395 (2005).
12. Metrangolo P, Meyer F, Pilati T, Resnati G, Terraneo G. Halogen bonding in supramolecular chemistry. Angew. Chem. Int. Ed. 47(33), 6114-6127 (2008).
13. Metrangolo P, Resnati G. Halogen Bonding: A paradigm in supramolecular chemistry. Chemistry 7(12), 2511-2519 (2001).
14. Hays FA, Vargason JM, Ho PS. Effect of sequence on the conformation of DNA holliday junctions. Biochemistry 42(32), 9586-9597 (2003).
15. Auffinger P, Hays FA, Westhof E, Ho PS. Halogen bonds in biological molecules. Proc. Natl Acad. Sci USA 101(48), 16789-16794 (2004).
16. Voth AR, Hays FA, Ho PS. Directing macromolecular conformation through halogen bonds. Proc. Natl Acad. Sci. USA 104(15), 6188-6193 (2007).
17. Voth AR, Khuu P, Oishi K, Ho PS. Halogen bonds as orthogonal molecular interactions to hydrogen bonds. Nat. Chem. 1(1), 74-79 (2009).
18. Wilcken R, Zimmermann MO, Lange A, Joerger AC, Boeckler FM. Principles and applications of halogen bonding in medicinal chemistry and chemical biology. J. Med. Chem. 56(4), 1363-1388 (2013).
19. Lu Y, Shi T, Wang Y et al. Halogen bonding, a novel interaction for rational drug design J. Med. Chem. 52(9), 2854-2862 (2009).
20. Parisini E, Metrangolo P, Pilati T, Resnati G, Terraneo G. Halogen bonding in halocarbon-protein complexes: A structural survey. Chem. Soc. Rev. 40(5), 2267-2278 (2011).
21. Hardegger LA, Kuhn B, Spinnler B et al. Systematic investigation of halogen bonding in protein-ligand interactions. Angew. Chem. Int. Ed. 50(1), 314-318 (2011).
22. Xu Z, Liu Z, Chen T et al. Utilization of halogen bond in lead optimization: A case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. J. Med. Chem. 54(15), 5607-5611 (2011).
23. Hernandes MZ, Cavalcanti SMT, Moreira DRM, De Azevedo WF, Leite ACL. Halogen atoms in the modern medicinal chemistry: Hints for the drug design. Curr. Drug Targets 11(3), 303-314 (2010).
24. Desiraju GR, Ho PS, Kloo L et al. Definition of the halogen bond (IUPAC Recommendations 2013). Pure Appl. Chem. 85(8), 1711-1713 (2013).
25. Murray J, Lane P, Clark T, Politzer P. σ-hole bonding: Molecules containing group VI atoms. J. Mol. Model. 13(10), 1033-1038 (2007).
26. Murray J, Lane P, Politzer P. Expansion of the σ-hole concept. J. Mol. Model. 15(6), 723-729 (2009).
27. Murray JS, Lane P, Clark T, Riley KE, Politzer P. Sigmaholes, pi-holes and electrostatically-driven interactions. J. Mol. Model. 18(2), 541-548 (2012).
28. Laaksonen L. A graphics program for the analysis and display of molecular dynamics trajectories. J. Mol. Graph 10(1), 33-34, 24 (1992).
29. V1.4, MOLCAD GmbH: Darmstadt, Germany. www. molcad.de
30. Rezac J, Riley KE, Hobza P. Benchmark calculations of noncovalent interactions of halogenated molecules. J. Chem. Theory Comput. 8(11), 4285-4292 (2012).
31. Kozuch S, Martin JML. Halogen bonds: benchmarks and theoretical analysis. J. Chem. Theory Comput. 9(4), 1918-1931 (2013).
32. Riley KE, Hobza P. The relative roles of electrostatics and dispersion in the stabilization of halogen bonds. Phys. Chem. Chem. Phys. 15(41), 17742-17751 (2013).
33. Møller C, Plesset MS. Note on an approximation treatment for many-electron systems. Phys. Rev. 46(7), 618-622 (1934).
34. Pople JA, Binkley JS, Seeger R. Theoretical Models Incorporating Electron Correlation. Int. J. Quantum Chem. 1-19 (1976).
35. Grimme S. Improved second-order Moller-Plesset perturbation theory by separate scaling of parallel-and antiparallel-spin pair correlation energies. J. Chem. Phys. 118(20), 9095-9102 (2003).
36. Weigend F, Ahlrichs R. Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy. Phys. Chem. Chem. Phys. 7(18), 3297-3305 (2005).
37. Peterson KA, Figgen D, Goll E, Stoll H, Dolg M. Systematically convergent basis sets with relativistic pseudopotentials. II. Small-core pseudopotentials and correlation consistent basis sets for the post-d group 16-18 elements. J. Chem. Phys. 119(21), 11113-11123 (2003).
38. Grimme S, Antony J, Ehrlich S, Krieg H. A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J. Chem. Phys. 132(15), 154104 (2010).
39. Wilcken R, Zimmermann M, Lange A, Zahn S, Boeckler F. Using halogen bonds to address the protein backbone: a systematic evaluation. J. Comput. Aided Mol. Des. 26(8), 935-945 (2012).
40. Lange A, Zimmermann MO, Wilcken R, Zahn S, Boeckler FM. Targeting histidine sidechains in molecular design through nitrogen-halogen bonds. J. Chem. Inf. Model. 53(12), 3178-3189 (2013).
41. Wilcken R, Zimmermann MO, Lange A, Zahn S, Kirchner B, Boeckler FM. Addressing Methionine in Molecular Design through Directed Sulfur-Halogen Bonds. J. Chem. Theory Comput. 7(7), 2307-2315 (2011).
42. Zhou P, Zou JW, Tian FF, Shang ZC. Fluorine bonding-how does it work in protein-ligand interactions J. Chem. Inf. Model. 49(10), 2344-2355 (2009).
43. Boys SF, Bernardi F. The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors. Mol. Phys. 19, 553-566 (1970).
44. Carter M, Ho PS. Assaying the energies of biological halogen bonds. Cryst. Growth Des. 11(11), 5087-5095 (2011).
45. Riley KE, Murray JS, Politzer P, Concha MC, Hobza P. Br-O complexes as probes of factors affecting halogen bonding: interactions of bromobenzenes and bromopyrimidines with acetone. J. Chem. Theory Comput. 5(1), 155-163 (2009).
46. Hennemann M, Murray JS, Politzer P, Riley KE, Clark T. Polarization-induced sigma-holes and hydrogen bonding. J. Mol. Model. 18(6), 2461-2469 (2012).
47. Riley KE, Murray JS, Fanfrlik J et al. Halogen bond tunability I: the effects of aromatic fluorine substitution on the strengths of halogen-bonding interactions involving chlorine, bromine, and iodine. J. Mol. Model. 17(12), 3309-3318 (2011).
48. Riley K, Murray J, Fanfrlík J et al. Halogen bond tunability II: the varying roles of electrostatic and dispersion contributions to attraction in halogen bonds. J. Mol. Model. 19, 4651-4659 (2013).
49. Fanfrlik J, Kolar M, Kamlar M et al. Modulation of aldose reductase inhibition by halogen bond tuning. ACS Chem. Biol. 8(11), 2484-2492 (2013).
50. Baumli S, Endicott JA, Johnson LN. Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem. Biol. 17(9), 931-936 (2010).
51. Herold JM, Wigle TJ, Norris JL et al. Small-molecule ligands of methyl-lysine binding proteins. J. Med. Chem. 54(7), 2504-2511 (2011).
52. Georgescu RE, Yurieva O, Kim S-S, Kuriyan J, Kong X-P, O'donnell M. Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp. Proc. Natl Acad. Sci. USA 105(32), 11116-11121 (2008).
53. PDB ID: 3TG6; Edavettal SC, Pearce BC, Lewis HA et al. Biophysical and structural characterization of a novel class of influenza virus inhibitors. www.rcsb.org/pdb/explore/explore.dostructureId=3TG6
54. Njoroge FG, Vibulbhan B, Pinto P et al. Enhanced FTase activity achieved via piperazine interaction with catalytic zinc. Bioorg. Med. Chem. Lett. 16(4), 984-988 (2006).
55. Liu L, Baase WA, Matthews BW. Halogenated benzenes bound within a non-polar cavity in T4 lysozyme provide examples of I...S and I...Se halogen-bonding. J. Mol. Biol. 385(2), 595-605 (2009).
56. Ryan A, Chung C-W, Curry S. Crystallographic analysis reveals the structural basis of the high-affinity binding of iophenoxic acid to human serum albumin. BMC Struct. Biol. 11(1), 18 (2011).
57. Zbinden KG, Anselm L, Banner DW et al. Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Eur. J. Med. Chem. 44(7), 2787-2795 (2009).
58. Melcher K, Xu Y, Ng L-M et al. Identification and mechanism of ABA receptor antagonism. Nat. Struct. Mol. Biol. 17(99), 1102-1108 (2010).
59. Akwabi-Ameyaw A, Bass JY, Caldwell RD et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg. Med. Chem. Lett. 18(15), 4339-4343 (2008).
60. Su D-S, Lim JJ, Tinney E et al. Substituted tetrahydroquinolines as potent allosteric inhibitors of reverse transcriptase and its key mutants. Bioorg. Med. Chem. Lett. 19(17), 5119-5123 (2009).
61. Berry R, Ding X, Shokhireva T, Weichsel A, Montfort W, Walker FA. Axial ligand complexes of the Rhodnius nitrophorins: reduction potentials, binding constants, EPR spectra, and structures of the 4-iodopyrazole and imidazole complexes of NP4. J. Biol. Inorg. Chem. 9(2), 135-144 (2004).
62. Hogner A, Kastrup JS, Jin R et al. Structural basis for AMPA receptor activation and ligand selectivity: crystal structures of five agonist complexes with the GluR2 ligand-binding core. J. Mol. Biol. 322(1), 93-109 (2002).
63. Cui JJ, Tran-Dubé M, Shen H et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54(18), 6342-6363 (2011).
64. PDB ID: 3FMD; Filippakopoulos P, Eswaran J, Keates T et al. Crystal structure of human haspin with an isoquinoline ligand. www.rcsb.org/pdb/explore/ explore. dostructureId=3FMD
65. Roehrig S, Straub A, Pohlmann J et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]- 1,3-oxazolidin-5-yl} methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48(19), 5900-5908 (2005).
66. Baum B, Mohamed M, Zayed M et al. More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the s1 pocket of thrombin. J. Mol. Biol. 390(1), 56-69 (2009).
67. Gussregen S, Matter H, Hessler G, Muller M, Schmidt F, Clark T. 3D-QSAR based on quantum-chemical molecular fields: toward an improved description of halogen interactions. J. Chem. Inf. Model. 52(9), 2441-2453 (2012).
68. Matter H, Nazare M, Gussregen S et al. Evidence for C-Cl/C-Br.pi interactions as an important contribution to protein-ligand binding affinity. Angew. Chem. Int. Ed. Engl. 48(16), 2911-2916 (2009).
69. Koeberle SC, Romir J, Fischer S et al. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat. Chem. Biol. 8(2), 141-143 (2012).
70. Fischer S, Wentsch HK, Mayer-Wrangowski SC et al. Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. J. Med. Chem. 56(1), 241-253 (2013).
71. Abu Thaher B, Arnsmann M, Totzke F et al. Tri-and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. J. Med. Chem. 55(2), 961-965 (2012).
72. Poznanski J, Shugar D. Halogen bonding at the ATP binding site of protein kinases: preferred geometry and topology of ligand binding. Biochim. Biophys. Acta 1834(7), 1381-1386 (2013).
73. Fedorov O, Huber K, Eisenreich A et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem. Biol. 18(1), 67-76 (2011).
74. Grant SK, Lunney EA. Kinase inhibition that hinges on halogen bonds. Chem. Biol. 18(1), 3-4 (2011).
75. Huber K, Brault L, Fedorov O et al. 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J. Med. Chem. 55(1), 403-413 (2011).
76. Jorgensen WL, Schyman P. Treatment of halogen bonding in the OPLS-AA force field: application to potent anti-HIV agents. J. Chem. Theory Comput. 8(10), 3895-3901 (2012).
77. Bollini M, Domaoal RA, Thakur VV et al. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J. Med. Chem. 54(24), 8582-8591 (2011).
78. Frey KM, Gray WT, Spasov KA et al. Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase. Chem. Biol. Drug Design (2013) doi:10.1111/cbdd.12266 (Epub ahead of print).
79. Wang XW, Zhang JF, Huang Y et al. Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile. J. Med. Chem. 55(5), 2242-2250 (2012).
80. Frey KM, Bollini M, Mislak AC et al. Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design. J. Am. Chem. Soc. 134(48), 19501-19503 (2012).
81. Rohde LA, Ahring PK, Jensen ML et al. Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine alpha4beta2 receptors: unique role of halogen bonding revealed. J. Biol. Chem. 287(6), 4248-4259 (2012).
82. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother. 56(5), 2326-2334 (2012).
83. Teng M, Hilgers MT, Cunningham ML et al. Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design. J. Med. Chem. 56(4), 1748-1760 (2013).
84. Anderson K, Chen Y, Chen Z et al. Pyrido[2,3-d] pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors. Bioorg. Med. Chem. Lett. 23(24), 6610-6615 (2013).
85. Rees DC, Congreve M, Murray CW, Carr R. Fragmentbased lead discovery. Nat. Rev. Drug Discov. 3(8), 660-672 (2004).
86. Jencks WP. On the attribution and additivity of binding energies. Proc. Natl Acad. Sci. USA 78(7), 4046-4050 (1981).
87. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28(7), 849-857 (1985).
88. Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 11(1), 29-34 (1991).
89. Fitzpatrick PA, Steinmetz AC, Ringe D, Klibanov AM. Enzyme crystal structure in a neat organic solvent. Proc. Natl Acad. Sci. USA 90(18), 8653-8657 (1993).
90. Mattos C, Ringe D. Locating and characterizing binding sites on proteins. Nat. Biotechnol. 14(5), 595-599 (1996).
91. English AC, Groom CR, Hubbard RE. Experimental and computational mapping of the binding surface of a crystalline protein. Protein Eng. 14(1), 47-59 (2001).
92. Eisen MB, Wiley DC, Karplus M, Hubbard RE. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 19(3), 199-221 (1994).
93. Lauri G, Bartlett PA. CAVEAT: a program to facilitate the design of organic molecules. J. Comput. Aided Mol. Des. 8(1), 51-66 (1994).
94. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274(5292), 1531-1534 (1996).
95. Carr RA, Congreve M, Murray CW, Rees DC. Fragmentbased lead discovery: leads by design. Drug Discov. Today 10(14), 987-992 (2005).
96. Schulz MN, Hubbard RE. Recent progress in fragmentbased lead discovery. Curr. Opin. Pharmacol. 9(5), 615-621 (2009).
97. Baker M. Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12(1), 5-7 (2013).
98. Leach AR, Hann MM. Molecular complexity and fragmentbased drug discovery: ten years on. Curr. Opin. Chem. Biol. 15(4), 489-496 (2011).
99. Macarron R, Banks MN, Bojanic D et al. Impact of highthroughput screening in biomedical research. Nat. Rev. Drug Discov. 10(3), 188-195 (2011).
100. Clark MA, Acharya RA, Arico-Muendel CC et al. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nat. Chem. Biol. 5(9), 647-654 (2009).
101. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467(7315), 596-599 (2010).
102. Chessari G, Woodhead AJ. From fragment to clinical candidate-a historical perspective. Drug Discov. Today 14(13-14), 668-675 (2009).
103. Reymond J-L, Van Deursen R, Blum LC, Ruddigkeit L. Chemical space as a source for new drugs. MedChemComm 1(1), 30-38 (2010).
104. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6(1), 29-40 (2007).
105. Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery Drug Discov. Today 8(19), 876-877 (2003).
106. Murray CW, Verdonk ML, Rees DC. Experiences in fragment-based drug discovery. Trends Pharmacol. Sci. 33(5), 224-232 (2012).
107. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41(3), 856-864 (2001).
108. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc. Natl Acad. Sci. USA 96(18), 9997-10002 (1999).
109. Hann MM, Keseru GM. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11(5), 355-365 (2012).
110. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004).
111. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnol. 18(10), 1105-1108 (2000).
112. Blundell TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1(1), 45-54 (2002).
113. Kuhn P, Wilson K, Patch MG, Stevens RC. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. 6(5), 704-710 (2002).
114. Wilcken R, Liu X, Zimmermann MO et al. Halogenenriched fragment libraries as leads for drug rescue of mutant p53. J. Am. Chem. Soc. 134(15), 6810-6818 (2012).
115. Liu X, Wilcken R, Joerger AC et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41(12), 6034-6044 (2013).
116. Pellecchia M, Sem DS, Wuthrich K. NMR in drug discovery. Nat. Rev. Drug Discov. 1(3), 211-219 (2002).
117. Lepre CA. Practical aspects of NMR-based fragment screening. Methods Enzymol. 493, 219-239 (2011).
118. Harner MJ, Frank AO, Fesik SW. Fragment-based drug discovery using NMR spectroscopy. J. Biomol. NMR 56(2), 65-75 (2013).
119. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA 105(30), 10360-10365 (2008).
120. Neumann T, Junker HD, Schmidt K, Sekul R. SPR-based fragment screening: advantages and applications. Curr. Top. Med. Chem. 7(16), 1630-1642 (2007).
121. Danielson UH. Fragment library screening and lead characterization using SPR biosensors. Curr. Top. Med. Chem. 9(18), 1725-1735 (2009).
122. Navratilova I, Hopkins AL. Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 1(1), 44-48 (2010).
123. Vedadi M, Niesen FH, Allali-Hassani A et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl Acad. Sci. USA 103(43), 15835-15840 (2006).
124. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2(9), 2212-2221 (2007).
125. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem. Biol. 17(1), 46-56 (2010).
126. Hann MM. Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2(5), 349-355 (2011).
127. Murray CW, Rees DC. The rise of fragment-based drug discovery. Nat. Chem. 1(3), 187-192 (2009).
128. Erlanson DA, Mcdowell RS, O'brien T. Fragment-based drug discovery. J. Med. Chem. 47(14), 3463-3482 (2004).
129. Wyss DF, Wang YS, Eaton HL et al. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. Top. Curr. Chem. 317, 83-114 (2012).
130. Hennig M, Ruf A, Huber W. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Top. Curr. Chem. 317, 115-143 (2012).
131. Wielens J, Headey SJ, Rhodes DI et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification J. Biomol. Screen. 18(2), 147-159 (2013).
132. Ruddigkeit L, Van Deursen R, Blum LC, Reymond JL. Enumeration of 166 billion organic small molecules in the chemical universe database GDB-17. J. Chem. Inf. Model. 52(11), 2864-2875 (2012).
133. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6(11), 881-890 (2007).
134. Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 8(3), 203-212 (2009).
135. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001).
136. Practical fragments: the-rule-of-three-at-ten. http://practicalfragments. blogspot.com/2013/07/the-rule-ofthree-at-ten.html
137. Jhoti H, Williams G, Rees DC, Murray CW. The 'rule of three' for fragment-based drug discovery: where are we now Nat. Rev. Drug Discov. 12(8), 644-645 (2013).
138. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 48(2), 403-413 (2005).
139. Over B, Wetzel S, Grutter C et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem. 5(1), 21-28 (2013).
140. Hung AW, Ramek A, Wang YK et al. Route to threedimensional fragments using diversity-oriented synthesis. Proc. Natl Acad. Sci. USA 108(17), 6799-6804 (2011).
141. Vulpetti A, Hommel U, Landrum G, Lewis R, Dalvit C. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. J. Am. Chem. Soc. 131(36), 12949-12959 (2009).
142. Jordan JB, Poppe L, Xia X et al. Fragment based drug discovery: practical implementation based on (1)(9)F NMR spectroscopy. J. Med. Chem. 55(2), 678-687 (2012).
143. Dauter Z, Dauter M, Rajashankar KR. Novel approach to phasing proteins: derivatization by short cryo-soaking with halides. Acta Crystallogr. D Biol. Crystallogr. 56(Pt 2), 232-237 (2000).
144. Beck T, Gruene T, Sheldrick GM. The magic triangle goes MAD: experimental phasing with a bromine derivative. Acta Crystallogr. D Biol. Crystallogr. 66(Part 4), 374-380 (2010).
145. Beck T, Krasauskas A, Gruene T, Sheldrick GM. A magic triangle for experimental phasing of macromolecules. Acta Crystallogr. D Biol. Crystallogr. 64(Pt 11), 1179-1182 (2008).
146. Blaney J, Nienaber V, Burley SK. Fragment-based lead discovery and optimization using X-ray crystallography, computational chemistry, and high-throughput organic synthesis. In: Fragment-based Approaches in Drug Discovery. Jahnke W, Erlanson DA (Eds). Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim, Germany, 215-248 (2006).
147. Bauman JD, Patel D, Arnold E. Fragment screening and HIV therapeutics. Top. Curr. Chem. 317, 181-200 (2012).
148. Tiefenbrunn T, Forli S, Happer M et al. Crystallographic fragment based drug discovery: use of a brominated fragment library targeting hiv protease. Chemical Biol. Drug Design 83(2), 141-148 (2013).
149. De Meijere A, Diederich F. Metal-Catalyzed Cross-Coupling Reactions (2nd Edition). Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim, Germany (2004).
150. Suzuki A. Recent advances in the cross-coupling reactions of organoboron derivatives with organic electrophiles, 1995-1998. J. Organomet. Chem. 576(1-2), 147-168 (1999).
151. Miyaura N, Suzuki A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 95(7), 2457-2483 (1995).
152. Negishi EI. Palladium-catalyzed or nickel-catalyzed cross coupling-a new selective method for carbon carbon bond formation. Acc. Chem. Res. 15(11), 340-348 (1982).
153. Negishi E, King AO, Okukado N. Selective carboncarbon bond formation via transition-metal catalysis .3. Highly selective synthesis of unsymmetrical biaryls and diarylmethanes by nickel-catalyzed or palladium-catalyzed reaction of aryl derivatives and benzylzinc derivatives with aryl halides. J. Org. Chem. 42(10), 1821-1823 (1977).
154. King AO, Okukado N, Negishi EI. Highly general stereoselective, regio-selective, and chemo-selective synthesis of terminal and internal conjugated enynes by Pd-catalysed reaction of alkynylzinc reagents with alkenyl halides. J. Chem. Soc. Chem. Commun. (19), 683-684 (1977).
155. Stille JK. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles. Angew. Chem. Int. Ed. 25(6), 508-523 (1986).
156. Suzuki A. Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides. Pure Appl. Chem. 63(3), 419-422 (1991).
157. Chinchilla R, Najera C. The Sonogashira reaction: a booming methodology in synthetic organic chemistry. Chem. Rev. 107(3), 874-922 (2007).
158. Li JH, Liang Y, Wang DP, Liu WJ, Xie YX, Yin DL. Efficient Stille cross-coupling reaction catalyzed by the Pd(OAc)2/Dabco catalytic system. J. Org. Chem. 70(7), 2832-2834 (2005).
159. Wolfe JP, Wagaw S, Marcoux J-F, Buchwald SL. Rational development of practical catalysts for aromatic carbon nitrogen bond formation. Acc. Chem. Res. 31(12), 805-818 (1998).
160. Burgos CH, Barder TE, Huang X, Buchwald SL. Significantly improved method for the Pd-catalyzed coupling of phenols with aryl halides: understanding ligand effects. Angew. Chem. Int. Ed. 45(26), 4321-4326 (2006).
161. Urgaonkar S, Xu JH, Verkade JG. Application of a new bicyclic triaminophosphine ligand in Pd-catalyzed Buchwald-Hartwig amination reactions of aryl chlorides, bromides, and iodides. J. Org. Chem. 68(22), 8416-8423 (2003).
162. Littke AF, Fu GC. Palladium-catalyzed coupling reactions of aryl chlorides. Angew. Chem. Int. Ed. Engl. 41(22), 4176-4211 (2002).
163. Bates RW, Gabel CJ, Ji J, Rama-Devi T. Synthesis of phenolic natural products using palladium catalyzed coupling reactions. Tetrahedron 51(30), 8199-8212 (1995).
164. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 77, 557-582 (2008).
165. Joerger AC, Fersht AR. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26(15), 2226-2242 (2007).
166. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19(10), 1245-1256 (2000).
167. Di Como CJ, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene 16(19), 2527-2539 (1998).
168. Joerger AC, Ang HC, Fersht AR. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl Acad. Sci. USA 103(41), 15056-15061 (2006).
169. Wilcken R, Wang G, Boeckler FM, Fersht AR. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc. Natl Acad. Sci. USA 109(34), 13584-13589 (2012).